Evidence map›Paper›PMID 37639975›Full record

ArticleBiomaterials2023

Injectable hydrogel for sustained delivery of progranulin derivative Atsttrin in treating diabetic fracture healing.

Lida Moradi, Lukasz Witek, Vasudev Vivekanand Nayak, Angel Cabrera Pereira, Ellen Kim, Julia Good, Chuan-Ju Liu

Open access · greenAbstract read
In one paragraph

Article in Biomaterials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Graphene Oxide: Preparation and Medical Research.Materials (Basel, Switzerland) · 2025
    Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Lida MoradiDepartment of Orthopaedics Surgery, New York University Grossman School of Medicine, New York, NY, 10003, USA; Department of Orthopaedics & Rehabilitation, Yale University School of Medicine, New Haven, CT, 06510, USA.
Lukasz WitekBiomaterials Division - Department of Molecular Pathobiology, New York University College of Dentistry, New York, NY, 10010, USA; Department of Biomedical Engineering, New York University Tandon School of Engineering, Brooklyn, NY, 11201, USA.
Vasudev Vivekanand NayakBiomaterials Division - Department of Molecular Pathobiology, New York University College of Dentistry, New York, NY, 10010, USA.
Angel Cabrera PereiraBiomaterials Division - Department of Molecular Pathobiology, New York University College of Dentistry, New York, NY, 10010, USA.
Ellen KimDepartment of Orthopaedics Surgery, New York University Grossman School of Medicine, New York, NY, 10003, USA.
Julia GoodDepartment of Orthopaedics Surgery, New York University Grossman School of Medicine, New York, NY, 10003, USA.
Chuan-Ju LiuDepartment of Orthopaedics Surgery, New York University Grossman School of Medicine, New York, NY, 10003, USA; Department of Orthopaedics & Rehabilitation, Yale University School of Medicine, New Haven, CT, 06510, USA; Department of Cell Biology, New York University Grossman School of Medicine, New York, NY, 10016, USA. Electronic address: chuan-ju.liu@yale.edu.
New York University · USYale University · US

Funding

The immunological mechanism of PGRNs anti-inflammatory effect - Renewal - 1R01AR062207 · NIAMS · YALE UNIVERSITY · PI Chuanju Liu · 2012 to 2026
$5.6M
The Role of PGRN Growth Factor in Osteoarthritis. - Renewal - 1 - Revision - 2R01AR061484 · NIAMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI LIU, CHUANJU · 2011 to 2020
$4.8M
The Role of Sodium Channel Nav1.7 in Osteoarthritis - Resubmission - 1R01AR078035 · NIAMS · YALE UNIVERSITY · PI Chuanju Liu, Stephen Waxman · 2022 to 2026
$2.8M
Targeting TNF Receptors to Inhibit Inflammation and to Prompt Bone Regeneration in Type 1 Diabetes - Resubmission - 1R01AR076900 · NIAMS · YALE UNIVERSITY · PI LIU, CHUANJU · 2020 to 2024
$2.0M
NIAMS NIH HHS R01 AR061484NIAMS NIH HHS R01 AR062207NIAMS NIH HHS R01 AR076900NIAMS NIH HHS R01 AR078035
6 · The paper itself

Abstract

Hydrogels with long-term storage stability, controllable sustained-release properties, and biocompatibility have been garnering attention as carriers for drug/growth factor delivery in tissue engineering applications. Chitosan (CS)/Graphene Oxide (GO)/Hydroxyethyl cellulose (HEC)/β-glycerol phosphate (β-GP) hydrogel is capable of forming a 3D gel network at physiological temperature (37 °C), rendering it an excellent candidate for use as an injectable biomaterial. This work focused on an injectable thermo-responsive CS/GO/HEC/β-GP hydrogel, which was designed to deliver Atsttrin, an engineered derivative of a known chondrogenic and anti-inflammatory growth factor-like molecule progranulin. The combination of the CS/GO/HEC/β-GP hydrogel and Atsttrin provides a unique biochemical and biomechanical environment to enhance fracture healing. CS/GO/HEC/β-GP hydrogels with increased amounts of GO exhibited rapid sol-gel transition, higher viscosity, and sustained release of Atsttrin. In addition, these hydrogels exhibited a porous interconnected structure. The combination of Atsttrin and hydrogel successfully promoted chondrogenesis and osteogenesis of bone marrow mesenchymal stem cells (bmMSCs) in vitro. Furthermore, the work also presented in vivo evidence that injection of Atsttrin-loaded CS/GO/HEC/β-GP hydrogel stimulated diabetic fracture healing by simultaneously inhibiting inflammatory and stimulating cartilage regeneration and endochondral bone formation signaling pathways. Collectively, the developed injectable thermo-responsive CS/GO/HEC/βG-P hydrogel yielded to be minimally invasive, as well as capable of prolonged and sustained delivery of Atsttrin, for therapeutic application in impaired fracture healing, particularly diabetic fracture healing.

Indexed as

ChitosanDiabetes MellitusFracture HealingGlycerophosphatesGraphiteHydrogelsProgranulinsbeta-glycerophosphoric acidChitosanGlycerophosphatesgraphene oxideGraphiteHydrogelsProgranulinsAtsttrinDiabetesFracture healingImpaired fracture healingInjectable hydrogelProgranulin

Identifiers

PMID37639975
PMCPMC11232488
OpenAlexW4386169977

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.